Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 9/20 | 0.42 |
| ▸ | THRA | P10827 | 8/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930958 | 0.91 | THRA (0.44) | MMEACECPA1ACE2THRB | |
| SCHEMBL4934220 | 0.90 | MME (0.42) | MMEACECPA1ACE2FFAR4 | |
| SCHEMBL5717725 | 0.89 | MRGPRX4 (0.36) | MMEACECPA1ACE2THRB | |
| SCHEMBL4930757 | 0.87 | THRB (0.49) | MMEACECPA1ACE2THRB | |
| SCHEMBL4922974 | 0.87 | THRB (0.39) | THRBTHRAMEN1KMT2AMCL1 | |
| SCHEMBL4933178 | 0.87 | THRB (0.48) | MMEACECPA1ACE2THRB | |
| SCHEMBL4932946 | 0.87 | MEN1 (0.40) | THRBTHRAMEN1KMT2AMCL1 | |
| SCHEMBL4928651 | 0.87 | THRB (0.46) | MMEACECPA1ACE2THRB | |
| SCHEMBL5106574 | 0.86 | THRB (0.42) | MMEACECPA1ACE2THRB | |
| SCHEMBL4933384 | 0.86 | THRB (0.44) | MMEACECPA1ACE2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092317-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | MME 2170/4885ACE 2985/4885CPA1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.